🔴 Xenetic Biosciences is trading 6.3% down today in pre-market after wider second-quarter loss

Xenetic Biosciences is trading 6.3% down at $2.97 in pre-market after August 7 second-quarter report highlighted a wider $0.9 million net loss.

• Royalty revenue rose 12% to approximately $0.7 million; strategic-review legal expenses increased costs, and cash declined to approximately $6.5 million.
• Positive DNase platform milestones and Israeli approval for a CAR-T exploratory study were reported.
• The decline appears company-specific after earnings; S&P 500 and Nasdaq futures were modestly higher, with no major August 10 announcement identified.